Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CART-19 for MRD+ CD19+ ALL
NCT03027739Phase 3Unknown
- Sponsor
- Fujian Medical University
- Start
- Nov 2016
- Primary completion
- Dec 2019
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 3 trial of anti-CD19 CAR-T cells in acute lymphoblastic leukemia (ALL), sponsored by Fujian Medical University. Status: unknown.
02
Drugs
anti-CD19 CAR-T cells
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT03027739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03027739.